GENMAB REPORTS DATA FROM HUMAX-CD20 STUDY

Genmab has reported positive results in the HuMax-CD20 Phase I/II dose-escalation study to treat patients with active rheumatoid arthritis. In patients who received two doses of HuMax-CD20, 77 percent obtained ACR20. Even on an intent-to-treat basis, which included six patients who did not receive both doses of HuMax-CD20, 63 percent obtained an ACR20. Among the seven placebo-treated patients, none achieved ACR20.

There were three dose levels tested in the study. In the lowest dose group, (300 mg), 75 percent of patients who received both doses obtained ACR20. In both the 700 and 1000 mg dose groups, 78 percent of patients who received both doses obtained ACR20. The study included 39 patients and 33 received either two infusions of HuMax-CD20 or placebo, given 2 weeks apart. The primary objective of the study was safety.